286 related articles for article (PubMed ID: 19616110)
1. A framework to assess the translation of safety pharmacology data to humans.
Valentin JP; Bialecki R; Ewart L; Hammond T; Leishmann D; Lindgren S; Martinez V; Pollard C; Redfern W; Wallis R
J Pharmacol Toxicol Methods; 2009; 60(2):152-8. PubMed ID: 19616110
[TBL] [Abstract][Full Text] [Related]
2. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
3. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
[TBL] [Abstract][Full Text] [Related]
4. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
[TBL] [Abstract][Full Text] [Related]
5. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
[TBL] [Abstract][Full Text] [Related]
6. Exploratory drug safety: a discovery strategy to reduce attrition in development.
Bass AS; Cartwright ME; Mahon C; Morrison R; Snyder R; McNamara P; Bradley P; Zhou YY; Hunter J
J Pharmacol Toxicol Methods; 2009; 60(1):69-78. PubMed ID: 19422924
[TBL] [Abstract][Full Text] [Related]
7. PK/PD modelling and simulations: utility in drug development.
Rajman I
Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
[TBL] [Abstract][Full Text] [Related]
8. How do the top 12 pharmaceutical companies operate safety pharmacology?
Ewart L; Gallacher DJ; Gintant G; Guillon JM; Leishman D; Levesque P; McMahon N; Mylecraine L; Sanders M; Suter W; Wallis R; Valentin JP
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):66-70. PubMed ID: 22510338
[TBL] [Abstract][Full Text] [Related]
9. Trends in safety pharmacology: posters presented at the annual meetings of the Safety Pharmacology Society 2001-2010.
Redfern WS; Valentin JP
J Pharmacol Toxicol Methods; 2011; 64(1):102-10. PubMed ID: 21635957
[TBL] [Abstract][Full Text] [Related]
10. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
Roses AD
Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
[TBL] [Abstract][Full Text] [Related]
11. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
Kuhlmann J
Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
[TBL] [Abstract][Full Text] [Related]
12. Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A.
Valentin JP; Bass AS; Atrakchi A; Olejniczak K; Kannosuke F
J Pharmacol Toxicol Methods; 2005; 52(1):22-9. PubMed ID: 15961324
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
[TBL] [Abstract][Full Text] [Related]
14. Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?
Pugsley MK; Authier S; Towart R; Gallacher DJ; Curtis MJ
J Pharmacol Toxicol Methods; 2009; 60(1):24-7. PubMed ID: 19616107
[TBL] [Abstract][Full Text] [Related]
15. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
[TBL] [Abstract][Full Text] [Related]
16. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
Bender A; Scheiber J; Glick M; Davies JW; Azzaoui K; Hamon J; Urban L; Whitebread S; Jenkins JL
ChemMedChem; 2007 Jun; 2(6):861-73. PubMed ID: 17477341
[TBL] [Abstract][Full Text] [Related]
17. Using exposure-response and biomarkers to streamline early drug development.
Venitz J
Ernst Schering Res Found Workshop; 2007; (59):47-63. PubMed ID: 17117714
[TBL] [Abstract][Full Text] [Related]
18. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
[TBL] [Abstract][Full Text] [Related]
19. The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.
Ewart L; Aylott M; Deurinck M; Engwall M; Gallacher DJ; Geys H; Jarvis P; Ju H; Leishman D; Leong L; McMahon N; Mead A; Milliken P; Suter W; Teisman A; Van Ammel K; Vargas HM; Wallis R; Valentin JP
Toxicol Sci; 2014 Dec; 142(2):427-35. PubMed ID: 25246669
[TBL] [Abstract][Full Text] [Related]
20. Organic chemistry in drug discovery.
MacCoss M; Baillie TA
Science; 2004 Mar; 303(5665):1810-3. PubMed ID: 15031494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
